New search Hide text from Guidelines
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTSThis group comprises preparations used in the treatment of neoplastic diseases, and immunomodulating agents.
Corticosteroids for systemic use, see H02.
L01 ANTINEOPLASTIC AGENTS
Combination products are classified in L01XY - Combinations of antineoplastic agents, except for combinations of monoclonal antibodies or antibody drug conjugates which are classified in L01FY.
Detoxifying agents used in connection with high dose treatment of antineoplastic agents are classified in V03AF (e.g. calcium folinate).
Radiopharmaceuticals used in the treatment of cancer are classified in V10X.
| DDDs have been established for the protein kinase inhibitors in L01E only. No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X. This is because of highly individualised use and wide dosage ranges. The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy. The consumption of antineoplastic agents is in some countries measured in grams. This is recommended as a method to be used internationally for these particular agents. |
L01B ANTIMETABOLITES
L01BA Folic acid analogues
Trimetrexate is classified in P01AX - Other agents against amoebiasis and other protozoal agents.
Pre-filled syringes/pens of methotrexate for use in non-cancer indications and all oral formulations are classified in L04AX03.
L01BB Purine analogues
Parenteral formulations of cladribine used in cancer are classified in this group, while oral formulations for multiple sclerosis are classified in L04AA.
L01BC Pyrimidine analogues
Fluorouracil for systemic and local treatment is classified here.
Last updated: 2024-01-26